![Hans Lennernäs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hans Lennernäs
Gründer bei Canthera AB
Aktive Positionen von Hans Lennernäs
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Recipharm Pharmaceutical Development AB | Direktor/Vorstandsmitglied | - | - |
Hans Lennernäs Biomedical AB
![]() Hans Lennernäs Biomedical AB Miscellaneous Commercial ServicesCommercial Services Hans Lennernäs Biomedical AB is a private company based in Uppsala, Sweden. The Swedish company provides medical research, development, and teaching services. Additionally, they own and manage real estate. | Direktor/Vorstandsmitglied | - | - |
Canthera AB
![]() Canthera AB Pharmaceuticals: MajorHealth Technology Canthera AB is a Swedish company that develops, manufactures, and wholesales pharmaceuticals and medical equipment. The private company is based in Uddevalla, Sweden. The company was founded by Hans Lennernäs. | Direktor/Vorstandsmitglied | - | - |
Gründer | - | - |
Karriereverlauf von Hans Lennernäs
Ehemalige bekannte Positionen von Hans Lennernäs
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Uppsala | Corporate Officer/Principal | - | - |
DuoCort Pharma AB
![]() DuoCort Pharma AB Pharmaceuticals: MajorHealth Technology DuoCort Pharma AB conducts research, development, training, marketing, and sales in the medical field. The firm operates drug development company focused on improving glucocorticoid therapy. It develops Plenadren, a once daily dual-release hydrocortisone replacement therapy for patients with chronic adrenal insufficiency. The company was founded on July 6, 2007 and is headquartered in Stockholm, Sweden. | Gründer | - | - |
Empros Pharma AB
![]() Empros Pharma AB Pharmaceuticals: MajorHealth Technology Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest. | Direktor/Vorstandsmitglied | - | - |
Gründer | - | - | |
NANOLOGICA AB | Direktor/Vorstandsmitglied | 01.01.2014 | - |
Independent Dir/Board Member | 01.01.2014 | - | |
LIDDS AB | Direktor/Vorstandsmitglied | 23.02.2010 | - |
Gründer | 01.01.2003 | - | |
Corporate Officer/Principal | 30.06.2011 | - |
Ausbildung von Hans Lennernäs
University of Uppsala | Doctorate Degree |
Statistik
International
Schweden | 9 |
Operativ
Director/Board Member | 6 |
Founder | 4 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 7 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LIDDS AB | Health Technology |
NANOLOGICA AB | Health Technology |
Private Unternehmen | 5 |
---|---|
Recipharm Pharmaceutical Development AB | Health Technology |
Empros Pharma AB
![]() Empros Pharma AB Pharmaceuticals: MajorHealth Technology Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest. | Health Technology |
Hans Lennernäs Biomedical AB
![]() Hans Lennernäs Biomedical AB Miscellaneous Commercial ServicesCommercial Services Hans Lennernäs Biomedical AB is a private company based in Uppsala, Sweden. The Swedish company provides medical research, development, and teaching services. Additionally, they own and manage real estate. | Commercial Services |
DuoCort Pharma AB
![]() DuoCort Pharma AB Pharmaceuticals: MajorHealth Technology DuoCort Pharma AB conducts research, development, training, marketing, and sales in the medical field. The firm operates drug development company focused on improving glucocorticoid therapy. It develops Plenadren, a once daily dual-release hydrocortisone replacement therapy for patients with chronic adrenal insufficiency. The company was founded on July 6, 2007 and is headquartered in Stockholm, Sweden. | Health Technology |
Canthera AB
![]() Canthera AB Pharmaceuticals: MajorHealth Technology Canthera AB is a Swedish company that develops, manufactures, and wholesales pharmaceuticals and medical equipment. The private company is based in Uddevalla, Sweden. The company was founded by Hans Lennernäs. | Health Technology |
- Börse
- Insiders
- Hans Lennernäs
- Erfahrung